Omocianine - Bayer Schering Pharma
Alternative Names: omocyanine; SF-64Latest Information Update: 17 Apr 2019
At a glance
- Originator Bayer Schering Pharma; Fuji Photo Film
- Developer Bayer HealthCare Pharmaceuticals
- Class Contrast media; Diagnostic agents; Imaging agents
- Mechanism of Action Tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 17 Apr 2019 Discontinued - Phase-I for Breast cancer (Diagnosis) in Germany (IV)
- 17 Apr 2019 Discontinued - Phase-I for Breast cancer (Diagnosis) in Netherlands (IV)
- 28 Feb 2011 No development reported - Phase-I for Breast cancer in Germany (IV)